All In MedTech

Device Trial Radar · NCT05745116

Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT

Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision

Last checked: Nov 19, 2026Latest source record: Feb 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

150

Planned (sponsor's estimate)

Start

Nov 7, 2022

Primary completion

Jul 31, 2023

Study completion Jul 31, 2023

Sponsor

Lead sponsor
Notal Vision Inc.Not on our public-company list
Sponsor type
Industry
First posted
Feb 27, 2023

More device trials from this sponsor

Design

Study type
Observational
FDA-regulated device
Yes
Who can join
All sexes
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Evaluation of Repeated, In-Clinic, Self-Imaging by DME Patients Using the Notal Vision Home OCT The purpose of this study is to collect data on the NVHO device at up to three sites.

Conditions

  • Diabetic Macular Edema

Interventions

  • Notal Vision Home OCTDevice

    Optical Coherence Tomography (OCT) was originally developed in 1991 as a non-invasive imaging technology to generate cross-sectional imagery of ocular tissues in vivo1. Cross-sectional visualization of the retina has proven to be a valuable tool in the identification and assessment of structural abnormalities that are not visible with ophthalmoscopic or biomicroscopic examination. OCT has become eye care professionals' leading diagnostic tool in the detection, diagnosis and treatment of retinal diseases and conditions, including age-related macular degeneration (AMD), Diabetic Macular Edema (DME), and Retina Vein Occlusion (RVO). Notal Vision, Inc. (Manassas, VA) is developing a Home Optical Coherence Tomography (OCT) System to allow OCT images to be captured on an OCT device placed in the patients' homes for daily scanning of eyes diagnosed with DME. This Home OCT allows visualization of retinal fluid in the central 10 degrees and is currently for investigational use only.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate subjects' ability to perform multiple OCT self-scanning following a self-tutorial on the Notal Vision Home OCT (NVHO)Time frame: within 2 hours of an office visit
  2. Evaluate the repeatability of the Notal OCT Analyzer (NOA) automatic fluid volume quantification in volume scan from self-scanning with the NVHO in the central 10 degrees of the macula of Diabetic Retinopathy (DR) patientsTime frame: within 2 hours of an office visit
  3. Compare fluid quantification in images from NVHO and a commercial OCTTime frame: within 2 hours of an office visit

1 more outcomes with a free account

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Elman Retina Group, PA

    Baltimore, Maryland · Recruiting

  • The Retina Group of Washington

    Fairfax, Virginia · Recruiting

  • Wagner Kapoor Research Institute

    Norfolk, Virginia · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.